The balanced chromosome aberrations, inv(16)(p13q22), is found in approximately 10-12% of de novo acute myeloid leukemia (AML) cases and is closely associated with the FAB subtype M4eo. Inv(16) results in the fusion of the CBFB gene at 16q22 to the smooth muscle myosin heavy chain (MYH11) gene at 16p13. Clinical studies have shown that patients with de novo AML with inv(16) achieve higher rates of complete remission (CR), and continuous CR when treated with high-dose cytarabine during the consolidation phase. 1 The inv(16) is otherwise rarely reported in therapy-related AML (t-AML) patients. It was observed in breast cancer or lymphoma patients treated with alkylating agents, topoisomerase II inhibitors and/or radiation therapy. The additional cytogenetic abnormalities, combined with inv(16), observed in 54% of patients, were a large predominance of trisomy 8, 21 and 22 and deletion of 7q, or trisomy 13. 2 But, there was no t-AML coexistence with inv(16) and t(9;22). Herein, a case of t-AML with inv(16), with the subsequent development of the t(9;22) abnormality, is reported.
A 43-year-old woman was diagnosed as having a stage IIIA follicular lymphoma in September 2003. The patient received eight cycles of the current standard chemotherapy regimen: fludarabine, mitoxantrone and dexamethasone, and obtained CR. In July 2004, 10 months after the start of chemotherapy, and with the lymphoma still in a state of CR, she developed pancytopenia. The blood counts showed anemia, with hemoglobin at 9.0 g/dl, thrombocytopenia of 38 Â 10 3 /ml and leukopenia of 3.2 Â 10 3 /ml, with a differential count containing 5% neutrophils, 34% lymphocytes, 1% eosinophils and 60% monocytes. Her bone marrow showed marked hypocellular marrow, with 10% blasts and 40% eosinophils. A cytogenetic study of the bone marrow revealed 46,XX,inv(16) (p13.1q22) [20] . The findings of fluorescence in situ hybridization (FISH), using a LSI CBFB dual color, break apart rearrangement probe (Vysis Inc., IL, USA), were consistent with inv(16). FISH, using a LSI BCR/ABL dual color, dual fusion probe (Vysis Inc.), was performed, but no fusion signal was detected. After 1 month, her leukocyte count had increased (10.2 Â 10 3 / ml). A repeat bone marrow study was performed. The marrow cellularity was nearly 100%, and a diagnosis of acute myelomonocytic leukemia with eosiniphilia concluded. The blasts were positive for CD33, CD13 and CD34. Analysis of 25 metaphases, using classical cytogenetics, revealed two additional subclones, those being trisomy 8/8q and variant type of t(9;22). The karyotype after G-banding was as follows: 46,XX,inv(16)(p13.1q22)[5]/47,idem, þ 8,t(9;22;14)(q34;q11.2; q22)[12]/46,idem,der(3)t(3;8)(p26;q11.2),t(9;22;14)(q34;q11.2; q22) [8] (Figure 1 ). RT-PCR and FISH study was performed at this time, which demonstrated the BCR rearrangement within the minor breakpoint region on chromosome 22. After induction chemotherapy with idarubicin and N 4 -behenoyl-1-b-D-arabinofuranosylcytosine, she attained CR. A molecular assessment of the response to the RT-PCR of BCR-ABL showed conversion to PCR-negative. The tyrosine kinase inhibitor, imatinib mesylate interim therapy was done after first CR and before transplantation. After one more course of combined chemotherapy, including mitoxantrone and cytosine arabinoside, she received an allogeneic bone marrow transplantation (BMT) from an HLAidentical brother, with a conditioning regimen of fludarabine (30 mg/kg/day for 5 days) and busulfex (3.2 mg/kg/day for 2 days). A total of 2.05 Â 10 8 /kg of donor bone marrow cells was infused. For graft-versus-host disease prophylaxis, short-term methotrexate and FK506 were administered. Engraftment was obtained at 21 days.
The co-association of the inv(16) and the t(9;22) in patients with AML has only been reported in nine patients (Table 1) . [3] [4] [5] All 9 patients presented with the M4eo FAB subtype, with the exception of one, who presented with the AML M1 phenotype. 6 Only p190
BCR-ABL rearrangement was detected by molecular assessment. All were de novo AML, and to our knowledge, no case related to previous treatment has been reported. Our patient showed pancytopenia 10 months after the start of chemotherapy, which contained the topoisomerase II inhibitor, mitoxantrone. Although topoisomerase II inhibitor relates to the direct presentation of an overt leukemic state without a proceeding myelodysplastic syndrome (MDS) phase, 1 this case unusually had a preleukemic phase showing a hypocellular marrow, with 10% blasts and 40% eosinophils. The bone marrow finings was mimicking the marrow relapse of primary Figure 1 G-banded karyotype of bone marrow cells showing 47,XX,inv(16)(p13.1q22), þ 8,t(9;22;14)(q34;q11.2;q22) (a) and 46,XX, inv(16)(p13.1q22),der(3)t(3;8)(p26;q11.2),t(9;22;14)(q34;q11.2;q22) (b).
Letters to the Editor lymphoma, because eosinophil infiltration is also commonly found in lymphoma cases. But, the cytogenetic results of 46,XX,inv(16)(p13.1q22) supported that the marrow was in a hypocellular preleukemic phase, which would be expected to progress to AML with inv(16). Just 1 month later, the marrow revealed M4eo findings, as expected. Moreover, two additional chromosomal changes were detected at this point of time, including trisomy 8/8q and variant type of t(9;22). Trisomy 8 is a well known secondary chromosomal abnormality in de novo AML and t-AML, but the late appearance of the t(9;22) is an unusual event in both conditions. The t(9;22)(q34;q11) represents 2% of all therapy-related MDS and t-AML. The t(9;22) was found to be significantly associated with previous therapy with topoisomerase II inhibitors. 7 The latency period of this case was short, 10 months, and rapid clonal changes developed 1 month later. The t(9;22), associated with the p190 BCR-ABL rearrangement, in this patient was a late appearing, therapy-related clonal evolution. The previously reported cases co-associated with the inv(16) and t(9;22) suggested that the t(9;22) could be a secondary event.
4,5 Our case provides the definite evidence of this suggestion by serial cytogenetic and morphologic evaluation at an interval of 1 month.
The response rates to intensive antileukemic chemotherapy in t-AML with inv(16) were comparable to those of de novo AML. In all, 85% of patients obtained complete remission after intensive chemotherapy. 2 Among de novo AML cases with concurrent inv(16) and Ph, long term survival may be possible with intensive high dose cytarabine-based chemotherapy. 4 One patient was effectively treated with imatinib mesylate combined with a course of idarubicine and cytarabine. 5 Our patient showed clonal evolution during a short period; thus, she underwent allogeneic BMT from sibling donor after her first consolidation chemotherapy, and still remains well 5 months after BMT with normal karyotype and molecular study. The ideal treatment modality still requires further study. This is the first report of coexistence of inv(16) and t(9;22) in t-AML. It is noteworthy that in this case only inv(16) was detected in preleukemic phase, so that t(9;22) is certainly a secondary event following inv(16) as suspected in previous reports. We make an additional remark that a preleukemic phase of bone marrow can mimic a marrow relapse of primary lymphoma. Thus, not only a morphologic evaluation but also cytogenetic study is necessary to study pancytopenia or leukocytosis followed by chemotherapy. Table 1 Previously In patients over the age of 60 years with acute myeloid leukemia (AML), treatment results are disappointing with only modest improvement over the last four decades. 1 In addition to the limited success rates after induction therapy, one major problem is that older adults have a high rate of relapse, and no clearly effective postremission therapy has been established. 2, 3 We recently reported the results of our randomized phase III AML HD98-B treatment trial. 4 In this study, we showed that the addition of all-trans retinoic acid (ATRA) to induction and first consolidation therapy significantly improved complete remission (CR) rates and survival in patients with AML (excluding acute promyelocytic leukemia (APL)) over the age of 60 years. The present report focuses on the second randomization of this trial that was performed to assess the role of a second intensive, intravenously (i.v.) given consolidation with idarubicin and etoposide versus a 1-year oral maintenance therapy with the same drugs.
Patients 61 years or older with de novo AML or refractory anemia with excess of blasts in transformation (RAEB-t) defined by the French-American-British (FAB) classification system, secondary AML (s-AML) with a preceding history of myelodysplasia, or therapy-related AML following treatment of primary malignant disease (t-AML) were eligible for entry into the trial. Patients with APL, patients with concomitant liver, renal or cardiac disease, and patients with a performance status WHO 42 were not included. The treatment schedule was as follows: after a first up-front randomization for the addition of ATRA to induction therapy with two cycles of ICE (idarubicin 12 mg/m Between August 1997 and April 2003, 329 patients were recruited. After two cycles of induction therapy 151 of 329 eligible patients achieved CR (46%). First consolidation therapy with HAM or A-HAM was given in 119 patients. After first consolidation therapy, randomization between IEiv versus IEpo was intended. Causes for not proceeding to randomization were allogeneic transplantation from an HLA-identical sibling donor (n ¼ 7), no informed consent (n ¼ 14), and relapse in two patients after first consolidation therapy. Finally, 96 patients were randomized between IEiv (n ¼ 47) and IEpo (n ¼ 49). Table 1 shows the clinical parameters according to second randomization.
Of 47 patients randomized to IEiv, three withdrew informed consent and received no further therapy, and two patients relapsed before the start of IEiv. Forty-two patients received IEiv in median 55 days (range: 40-89 days) after first consolidation therapy with HAM or A-HAM. All patients were treated inhospital, and the median duration of hospital stay was 29 days (range, 7-42 days). All patients suffered from hematological toxicity with median times of neutropenia (neutrophils o0.5 Â 10 9 /l) and thrombocytopenia (platelets o20 Â 10 9 /l) of 13 (range, 1-27 days) and 7.5 days (range, 0-26 days), respectively. In 26 of 42 patients (62%), i.v. antibiotics were administered due to neutropenic fever (n ¼ 15), septicemia (n ¼ 4), pneumonia (n ¼ 4), and soft tissue infection (n ¼ 3). There was one death 12 days after start of IEiv due to pneumonia and subsequent septicemia.
Of 49 patients randomized to IEpo, three received intensive late consolidation (IEiv, n ¼ 2; HAM, n ¼ 1), and two patients relapsed before the start of IEpo. Forty-four patients received the first cycle of IEpo in median 55 days (range 25-268 days) after first consolidation therapy. A median of four cycles (range, one to 12) of IEpo were administered; eight patients completed 12 cycles of IEpo. Causes of premature termination of IEpo were relapse in 34 cases, persistent thrombocytopenia below 50 Â 10 9 /l after the forth cycle in one case, and infectious spondylitis after the second cycle in one case. A total of 251 cycles IEpo were administered. No hematological toxicity WHO grade III/IV was observed in patients who were in continuous CR. Four patients were admitted to the hospital due to fever (438.01C) and one due to infectious spondylitis, and all received i.v. antibiotics (11%). The median duration of their hospital stays was 6 days (range 3-9 days).
The median estimated follow-up time after second randomization was 52 months. Seventy-one of the 96 patients have died resulting in an estimated survival probability after 48 months of 24% (95 confidence interval, 17-36%). Of the 96 randomized patients, 80 relapsed, and one patient died during IEiv-induced cytopenia leading to a cumulative incidence of relapse (CIR) and death after 48 months of 82% (standard error, 0.04) and 1% (standard error, 0.01), respectively. Of the 80 relapsed patients, 39 received either no or palliative treatment. Following an intensive reinduction therapy, 13 of 41 (32%) patients achieved
